These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 26683263)
21. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168 [TBL] [Abstract][Full Text] [Related]
23. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA; BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708 [TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914 [TBL] [Abstract][Full Text] [Related]
26. [Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases]. Kaibori M; Iwamoto S; Ishizaki M; Matsui K; Saito T; Yoshioka K; Kwon AH Gan To Kagaku Ryoho; 2009 Dec; 36(13):2579-82. PubMed ID: 20009458 [TBL] [Abstract][Full Text] [Related]
27. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers. Nagayama S; Hasegawa S; Hida K; Kawada K; Hatano E; Nakamura K; Seo S; Taura K; Yasuchika K; Matsuo T; Zaima M; Kanazawa A; Terajima H; Tada M; Adachi Y; Nishitai R; Manaka D; Yoshimura T; Doi K; Horimatsu T; Mitsuyoshi A; Yoshimura K; Niimi M; Matsumoto S; Sakai Y; Uemoto S Int J Clin Oncol; 2017 Apr; 22(2):316-323. PubMed ID: 27752787 [TBL] [Abstract][Full Text] [Related]
28. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases]. Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977 [TBL] [Abstract][Full Text] [Related]
29. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy]. Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358 [TBL] [Abstract][Full Text] [Related]
30. [Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases]. Frena A; Martin F; La Guardia G; Vezzali N; Bonatti G; Stocker J; Graiff C Chir Ital; 2004; 56(3):351-7. PubMed ID: 15287631 [TBL] [Abstract][Full Text] [Related]
31. [Four Cases of Locally Advanced Colorectal Cancer Resected after Neoadjuvant Chemotherapy with mFOLFOX6 plus Bevacizumab]. Doi Y; Suzuki Y; Sugano N; Yamaoku K; Takata K; Matsuura H; Yoneyama K; Kameda Y; Rino Y; Masuda M Gan To Kagaku Ryoho; 2017 Nov; 44(12):1414-1416. PubMed ID: 29394652 [TBL] [Abstract][Full Text] [Related]
32. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer. Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185 [TBL] [Abstract][Full Text] [Related]
33. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624 [TBL] [Abstract][Full Text] [Related]
34. Multicentre study of perioperative Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094 [TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602 [TBL] [Abstract][Full Text] [Related]
36. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833 [TBL] [Abstract][Full Text] [Related]
37. Unresectable liver metastases in colorectal cancer: review of current strategies. Sueur B; Pellerin O; Voron T; Pointet AL; Taieb J; Pernot S Minerva Chir; 2016 Dec; 71(6):382-397. PubMed ID: 27733753 [TBL] [Abstract][Full Text] [Related]
38. Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). Oki E; Emi Y; Miyamoto Y; Kabashima A; Higashi H; Ogata Y; Ikebe M; Saeki H; Tokunaga S; Shirabe K; Beppu T; Uchida S; Takatsuki M; Sakoda M; Eguchi S; Akagi Y; Kakeji Y; Baba H; Natsugoe S; Maehara Y; Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1067-74. PubMed ID: 26334293 [TBL] [Abstract][Full Text] [Related]
39. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Pozzo C; Barone C; Kemeny NE Cancer Treat Rev; 2008 Jun; 34(4):293-301. PubMed ID: 18291590 [TBL] [Abstract][Full Text] [Related]
40. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases. Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]